BioScrip (BIOS) Misses Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
BioScrip Reports Fourth Quarter 2015 Financial Results
March 2, 2016 4:30 PM ESTQ4 Consolidated Adjusted EBITDA of $9.0 Million
Reaffirms 2016 Adjusted EBITDA Guidance of Between $50 Million - $60 Million
DENVER, March 02, 2016 (GLOBE NEWSWIRE) -- BioScrip, Inc. (NASDAQ: BIOS) (BioScrip or the Company) today announced financial results for the fourth quarter and full year 2015. For the fourth quarter, the Company reported revenue from continuing operations of $243.8 million, net loss from continuing operations of ($19.1) million and diluted EPS of ($0.28) loss per share. Excluding restructuring costs, the Company reported normalized net loss from continuing operations for the quarter of ($9.2) million and normalized diluted EPS of ($0.13) loss per share.                               ... More
